Pharmacotherapy in Down's syndrome: which way forward? (Q48677407)

14 February 2018

title

Pharmacotherapy in Down's syndrome: which way forward? (English)

1 reference

14 February 2018

0 references

1

1 reference

14 February 2018

Jamie O Edgin

series ordinal

2

object named as

Jamie O Edgin

1 reference

14 February 2018

publication date

1 July 2016

1 reference

14 February 2018

published in

Lancet Neurology

1 reference

14 February 2018

volume

15

1 reference

14 February 2018

issue

8

1 reference

14 February 2018

page(s)

776-777

1 reference

14 February 2018

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Molecular mapping of twenty-four features of Down syndrome on chromosome 21.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Cued recall in early-stage dementia in adults with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Assessing cognitive improvement in people with Down syndrome: important considerations for drug-efficacy trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

The importance of understanding individual differences in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

Obstructive sleep apnea syndrome and cognition in Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2930056-4

7 January 2021

10.1016/S1474-4422(16)30056-4

Identifiers

DOI

1 reference

14 February 2018

release_34lyhvdw6ramvjoxzs24zixcr4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/34lyhvdw6ramvjoxzs24zixcr4

24 November 2022

mapped directly with Wikidata item

PubMed ID

27302343

1 reference

14 February 2018